GlassScriptPhysician profile
Carly Jones
NPI 1205557683
$1,092.10
in general payments reported to CMS, 2019-2025
10 companies · $559 in 2025
The $559 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.96 · 2024: $515 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.13 |
| Education | $258.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $260.84 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $258.97 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $210.64 | 2024-2025 | |
| Glaxosmithkline, LLC. | $105.85 | 2024-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $105.27 | 2024-2025 | Dupixent |
| Kaleo, INC. | $60.46 | 2023-2024 | Auvi-Q |
| Optinose US, INC. | $41.93 | 2025 | |
| Hikma Pharmaceuticals USA | $17.03 | 2024 | Ryaltris |
| Astrazeneca Pharmaceuticals LP | $16.76 | 2025 | Fasenra |
| Ars Pharmaceuticals Operations, INC. | $14.35 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.